Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and ...
Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with recently disclosed evidence of persistent local immune remodeling, these ...
ECB opens digital euro platform applications for AI agent payments, machine transactions, and conditional payments. Deadline ...
New data suggest that givinostat treatment may slow the decline of upper limb function in boys with Duchenne muscular dystrophy compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results